Abstract:One of the most feared complications in medicine is sudden death caused by drug-induced proarrhythmia. Accordingly, concerted efforts have been made to define a drug’s proarrhythmic potential before regulatory approval. Monitoring for QT prolongation is one such method. Patients with heart failure represent a particularly high-risk population for torsade de pointes because of structural and electric remodeling that impair repolarization reserve. However, these patients are frequently excluded from clinical trials. Preclinical models simulate some of the electric remodeling of heart failure and form an important part of safety evaluations during early drug development. Clinical programs usually include a thorough QT study, which attempts to find a small mean change in QTc that serves as a surrogate for the risk of torsade de pointes. The impairment of repolarization reserve in heart failure goes beyond QT prolongation, however, and other clinical methods of measuring this propensity may be necessary to obtain a complete picture of a drug’s arrhythmic potential. Heart failure (HF) is a common and serious affliction. HF is a listed diagnosis in as many as 65% to 70% of hospital admissions each year in the United States.1 The prevalence of this disease continues to increase because of to a rise in coronary artery disease and diabetes incidence, an increase in the age of the population, and a reduction in the probability of sudden cardiac death (SCD) in HF with aggressive use of implantable cardioverter-defibrillators. The net result is a larger population of patients living longer with more comorbidities, and, as a corollary, more polypharmacy. HF has been recognized as one of several clinical risk factors for druginduced proarrythmia.2,3 Many classes of drugs have been shown to improve all-cause mortality in HF and have revolutionized both the treatment and prognosis of this condition. Although there is a need for continued development of drug treatments for HF, we must ensure that these treatments do not increase the risk for life-threatening arrhythmias. Assessing this risk accurately, however, has proven challenging. Although antiarrhythmic drugs are understood to have proarrhythmic potential, it has only recently been understood that noncardiac drugs also carry such risk. The withdrawal of terfenadine (Seldane) from the market in 1998 due to several cases of torsade de pointes (TdP) markedly heightened awareness that such drugs can be cardiotoxic. Since then, numerous noncardiac drugs have been withdrawn from the market because of a TdP risk, including prenylamine, cisapride, and sparfloxacin. In a large sample of patients treated between 1995 and 2003, the use of QT-prolonging drugs in the general population was associated with a significantly increased risk of SCD.4 In patients with coronary artery disease, the use of QTprolonging drugs confers a higher risk of SCD, especially in patients with diabetes mellitus.5 This has led to increased oversight by regulatory bodies. Concern about proarrhythmia has become the most common reason for drug nonapproval since the turn of the century.6 The most important predictor of TdP is QT interval prolongation, and therefore TdP and drug-induced QT prolongation have become virtually synonymous. There appear to be 3 components that are necessary for the genesis of TdP: lengthening of the cardiac action potential duration (APD), early afterdepolarizations (EAD), and transmural dispersion of repolarization allowing for propagation of the EAD and reentry.7 Clinical risk factors for TdP, as described by Roden, include HF, which, in many ways, is an excellent example of how 1 or more of these requisite conditions can be met.2 This article will discuss the cellular basis for repolarization abnormalities in HF, the preclinical assessment of TdP risk including in vitro and in vivo models, clinical assessments including the thorough QT study, ideas for refinement of the process, and finally, examples of emerging HF treatments and how their liabilities are being assessed.

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia

Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors

Drug-induced QT interval prolongation in patients with heart failure with preserved ejection fraction

Development of a Patient-Specific P.d85n-Potassium Voltage-Gated Channel Subfamily E Member 1–induced Pluripotent Stem Cell–Derived Cardiomyocyte Model for Drug-Induced Long QT Syndrome

Assessment of Dofetilide or Sotalol Tolerability in the Elderly

Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease

QTc Prolongation and Torsades De Pointes Due to a Coadministration of Fluoxetine and Amiodarone in a Patient with Implantable Cardioverter-Defibrillator Case Report and Review of the Literature

COMBINATION THERAPY WITH DOFETILIDE AND MEXILETINE FOR ATRIAL FIBRILLATION: INCREASED EFFICACY AND DECREASED QT INTERVAL PROLONGATION

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators

Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function

Assessment of the Proarrhythmic Potential of the Novel Antiarrhythmic Agent AZD7009 and Dofetilide in Experimental Models of Torsades De Pointes

Influence of OATP1B1 and OATP1B3 Mutations and Glomerular Filtration Rate on Trough Serum Digoxin Concentration in the Chinese Population

Impact of Direction of Transport on the Evaluation of Inhibition Potencies of Multidrug and Toxin Extrusion Protein 1 Inhibitors

Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in Andersen Tawil Syndrome

GW24-e2999 Proarrhythmic window of a drug determines the risk of multiple ion channel inhibitors

Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review

Human-induced pluripotent stem cell-derived cardiomyocytes: Cardiovascular properties and metabolism and pharmacokinetics of deuterated mexiletine analogs

Optical Mapping of the Effect of Pacing Rate and Ikr Blocker, Dofetilide, on Heterogeneity of Action Potential Duration Between Rabbit Right and Left Ventricle

Development of Therapeutics for Heart Failure